Biotechnology Analyst Minter discusses key considerations for Praxis’ Essential 1 Trial of PRAX-944 in essential tremor ahead of top-line data expected this quarter on an Analyst/Industry conference call to be held on January 27 at 2 pm. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRAX:
- Praxis Precision Medicines participates in a conference call with Piper Sandler
- Praxis Precision Medicines management to meet with Piper Sandler
- Praxis in strategic epilepsy pact with UCB for up to $100M potential
- Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
- Praxis to advance PRAX-562 Phase 2 study in pediatric patients